Sana Khan

Sana Khan

Auto-generated profile, based on publicly available information

Sana Khan

Lakeland Regional Health Medical Center

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
SHSangho Hyun
Sangho Hyun
CSChia‐Hung Sze
Chia‐Hung Sze
TKTughral Khan
Tughral Khan
JIJohn Iwaniec
John Iwaniec
SKSana Khan
Sana Khan
ABAnas Bizanti
Anas Bizanti
Background: Cardiovascular–kidney–metabolic (CKM) syndrome staging integrates adiposity, metabolic dysfunction, chronic kidney disease, and cardiovascular disease. Contemporary national estimates of CKM stage distribution, stage drivers, and treatment gaps are needed to inform implementation of the CKM framework. Methods: We analyzed adults aged ≥20 years in the National Health and Nutrition Examination Survey 2021 to 2023 fasting subsample. CKM stage was assigned hierarchically using American Heart Association CKM staging criteria. We estimated survey‐weighted CKM stage prevalence, national population counts, stage‐specific drivers, and risk‐factor control and treatment gaps across stages 2 through 4. Results: The analytic sample included 2958 adults, representing 245.2 million US adults. Overall, 26.4 million adults (10.8%) were stage 0, 56.8 million (23.2%) stage 1, 125.9 million (51.3%) stage 2, 13.4 million (5.5%) stage 3, and 22.7 million (9.3%) stage 4. Stage ≥1 was present in 89.2%, stage ≥2 in 66.1%, and advanced CKM (stages 3–4) in 14.7%. Among stage 1 adults, 85.1% had adiposity and 49.2% had prediabetes. Among adults with stage 2 CKM, hypertension (72.0%), metabolic syndrome (56.1%), and hypertriglyceridemia (41.9%) were common drivers. Among adults with stage 3 CKM, 95.8% met the Predicting Risk of Cardiovascular Disease Events 10‐year cardiovascular disease risk criterion. Risk‐factor control and treatment gaps were common across stages 2 through 4, including blood pressure ≥130/80 mm Hg in 50.3% to 66.9%, lipid‐lowering therapy nonuse among eligible adults in 30.1% to 59.2%, and low‐density lipoprotein cholesterol above the target in 64.5% to 73.9%. Conclusions: CKM syndrome affects most US adults, with stage‐specific drivers and persistent risk‐factor control and treatment gaps. These findings provide contemporary benchmarks for CKM surveillance and implementation.

12 March 2026 in Kidney360
Verified
Journal Article
Open access
ALAndrew Lurie
Andrew Lurie
ISIdys Solis
Idys Solis
PDPadideh Daneii
Padideh Daneii
SKSana Khan
Sana Khan
CIChidozie Igbonagwam
Chidozie Igbonagwam
ABAnas Bizanti
Anas Bizanti
Background: Desmopressin has a theoretical rationale to reduce procedural bleeding risk but results from randomized controlled trials are mixed. Methods: PubMed, EMBASE, and Google Scholar were searched on October 27, 2025 to identify studies evaluating Desmopressin administered prior to kidney biopsy. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Statistical analysis was performed using RevMan software to calculate Odd’s Ratios and assess heterogeneity with the I 2 statistic. Publication bias was assessed with Egger’s test. A sensitivity analysis was performed due to heterogeneity via the leave-one-out method with revised estimated odds presented thereafter. Results: 17 studies including 5394 participants were analyzed. The pooled estimated odds ratio (OR) for total bleeding was 0.89 [0.59 - 1.36], p = 0.60, I 2 = 85%. In subgroup analysis the pooled estimated OR for subcutaneous administration was 0.37 [0.21 - 0.65], p < 0.001, I 2 = 0%); intravenous administration was 1.47 [1.05 - 2.05], p =0.03, I 2 = 61%; intranasal administration was 0.68 [0.30 - 1.56], p = 0.37, I 2 = 87%; and estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m 2 was 0.74 [0.40 - 1.37 p =0.34, I 2 = 81%. After sensitivity analysis the revised OR for intranasal administration was 0.42 [0.31 - 0.59], p <0.001 and for eGFR < 60 was 0.55 [0.38 - 0.81], p = 0.002. The pooled estimated OR for severe hyponatremia was 3.85 (95% CI [2.12 - 7.00], p <0.001, I 2 = 33%. Conclusions: Overall there was no reduction in odds of bleeding but with high between-group heterogeneity. There were lower odds of bleeding in the intranasal and subcutaneous administration subgroups. Desmopressin resulted in higher odds of hyponatremia.